Singapore whistling as Penthrox arrives

Wilson Asset Management

Wilson Asset Management

Medical device manufacturer Medical Developments International (ASX:MVP) has received regulatory approval from the Health Sciences Authority in Singapore to market and sell Penthrox. MVP is the only global supplier of Penthrox, an emergency pain relief device developed in Australia and commonly known as “the green whistle”. The approval follows the recent European licence, development and commercialisation agreement that was finalised between MVP and Mundipharma International, with Mundipharma paying MVP upfront and milestone payments of up to $54.5 million US dollars. MVP shares have risen significantly in September, and closed up 9.8% for the week. We own MVP in the investment portfolio.

1 topic

1 stock mentioned

Wilson Asset Management
Wilson Asset Management

Wilson Asset Management has a track record of making a difference for shareholders and the community for more than 20 years. As the investment manager for eight leading LICs – WAM Capital (ASX: WAM), WAM Leaders (ASX: WLE), WAM Global (ASX: WGB),...

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.


Please sign in to comment on this wire.

trending on livewire
Get the best of Livewire by signing up to our popular daily newsletter